Literature DB >> 21604979

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.

Ee Lyn Su1, Matthew D Snape.   

Abstract

Although meningococcal disease caused by serogroup B remains an important public health concern, a licensed vaccine providing broad protection against this pathogen is not yet available. Advances in genomics have paved the way for the discovery of new vaccine candidates for inclusion into a multicomponent serogroup B vaccine. In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21604979     DOI： 10.1586/erv.11.32

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  9 in total

1.  Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.

Authors:  Brian D Plikaytis; Maria Stella; Giuseppe Boccadifuoco; Lisa M DeTora; Mauro Agnusdei; Laura Santini; Brunella Brunelli; Luca Orlandi; Isabella Simmini; Marzia Giuliani; Morgan Ledroit; Eva Hong; Muhamed-Kheir Taha; Kim Ellie; Gowrisankar Rajam; George M Carlone; Heike Claus; Ulrich Vogel; Ray Borrow; Jamie Findlow; Stefanie Gilchrist; Paola Stefanelli; Cecilia Fazio; Anna Carannante; Jan Oksnes; Elisabeth Fritzsønn; Anne-Marie Klem; Dominique A Caugant; Raquel Abad; Julio A Vázquez; Rino Rappuoli; Mariagrazia Pizza; John J Donnelly; Duccio Medini
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

2.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

3.  From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease.

Authors:  Maria Major; Steven Moss; Ronald Gold
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

4.  Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).

Authors:  S Ben-Shimol; R Dagan; Y Schonmann; N Givon-Lavi; N Keller; C Block; I Kassis; M Ephros; D Greenberg
Journal:  Infection       Date:  2013-03-10       Impact factor: 3.553

5.  Isolation of Chlamydia trachomatis and membrane vesicles derived from host and bacteria.

Authors:  Kyla Frohlich; Ziyu Hua; Jin Wang; Li Shen
Journal:  J Microbiol Methods       Date:  2012-08-30       Impact factor: 2.363

Review 6.  Role of microparticles in dengue virus infection and its impact on medical intervention strategies.

Authors:  Kristina Bargeron Clark; Hui-Mien Hsiao; Sansanee Noisakran; Jih-Jin Tsai; Guey Chuen Perng
Journal:  Yale J Biol Med       Date:  2012-03-29

Review 7.  Targeting the bacteria-host interface: strategies in anti-adhesion therapy.

Authors:  Anne Marie Krachler; Kim Orth
Journal:  Virulence       Date:  2013-05-15       Impact factor: 5.882

Review 8.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

9.  Effect of complement Factor H on antibody repertoire and protection elicited by meningococcal capsular group B vaccines containing Factor H binding protein.

Authors:  Peter T Beernink
Journal:  Hum Vaccin Immunother       Date:  2019-10-22       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.